The study aims to evaluate the safety and efficacy of the CHECKvacc drug when administered within a tumour against metastatic TNBC.Imugene (IMU) doses its second patient in the phase one clinical trial of its CHECKvacc drug candidate on patients with triple negative breast cancer (TNBC).CGA Contango Asset Management (ASX:CGA) inks two new partnerships.PAN Panoramic Resources' (ASX:PAN) first Savannah shipment sets sail.FML Focus Minerals (ASX:FML) raises $25.5m through entitlement offer.AL8 Alderan Resources (ASX:AL8) to focus on future drilling on Drum and Mizpah prospects.TBN Two wells flow gas to surface at Tamboran (ASX:TBN) and Santos (ASX:STO) JV.TRJ Trajan Group (ASX:TRJ) acquires Neoteryx.SFR Sandfire Resources (ASX:SFR) receives MATSA acquisition approval from Spanish government.SRN Surefire Resources (ASX:SRN) granted exploration license.RHT Resonance Health (ASX:RHT) receives US FDA approval for LiverSmart.ODA Orcoda (ASX:ODA) launches 'Notify' app for transport sector.CTM Centaurus Metals (ASX:CTM) begins trading on OTCQX.EMD Emyria (ASX:EMD) appoints Sixty Two Capital as corporate advisor for next phase of growth.

CZL Consolidated Zinc's (ASX:CZL) Plomosas mine only operated for 5 days this month.AT1 Atomo Diagnostics (ASX:AT1) hits back at market enquiry.SGM Sims Limited (ASX:SGM) sells 50.46 per cent stake in U.S.

Canvas x trial